Annual report
7133.TEDINET S100TIAQ
Period2023-04-01 → 2024-03-31
Filed2024-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks17 of 17 passed
Key figures · 104
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Operating income | ¥711m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥717m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥655m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥441m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥441m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥6.4bn | at 2024-03-31 | Cons. | Assets |
| Total liabilities | ¥4.7bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.6bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.5bn | at 2023-03-31 | Cons. | Net assets |
| Cash and deposits | ¥688m | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥688m | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥568m | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥707m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥539m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥62.05 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥59.26 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥231.46 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 25.9% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 26.8% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 544 | at 2024-03-31 | Cons. | Number of employees |
| Revenue | ¥8.3bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥6.7bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥5.8bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥707m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥530m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥719m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥558m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥506m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥251m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥122m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥655m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥534m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥441m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥383m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥328m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥97m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥33m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥4.4bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥2.9bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥2.5bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.0bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.8bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥2.8bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.4bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.6bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.5bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.1bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥609m | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥503m | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥661m | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥568m | at 2023-03-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥568m | at 2023-03-31 | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥720m | at 2022-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥538m | at 2021-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥227m | at 2020-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥342m | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥485m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥352m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥35m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥383m | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥320m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥78m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥165m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥111m | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥17m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥37m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6m | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥62.06 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.92 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥47.9 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.99 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.9 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥59.28 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥50.82 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥43.32 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥231.48 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥207.61 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥153.22 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥178.69 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥151.36 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 37.0% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.9% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.4% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 28.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 30.0% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 39.1% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.5% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.8% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 7,246,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,572,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,499,100 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,369 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,074 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 544 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 442 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 329 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 312 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 283 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥6m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 18 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥35m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥35m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥61m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | −¥9m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥8m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥8m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥854m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥409m |
| Home Visit Pharmacist Servicereportable segment | capex | 2023-04-01 → 2024-03-31 | ¥317m |
| Home Visit Pharmacist Servicereportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥84m |
| Home Visit Pharmacist Servicereportable segment | employees | at 2024-03-31 | 323 pure |
| Home Visit Pharmacist Servicereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥6.5bn |
| Home Visit Pharmacist Servicereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥6.5bn |
| Home Visit Pharmacist Servicereportable segment | segment assets | at 2024-03-31 | ¥2.0bn |
| Home Visit Pharmacist Servicereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥635m |
| Kirari Primereportable segment | capex | 2023-04-01 → 2024-03-31 | ¥116m |
| Kirari Primereportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥26m |
| Kirari Primereportable segment | employees | at 2024-03-31 | 27 pure |
| Kirari Primereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥837m |
| Kirari Primereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥837m |
| Kirari Primereportable segment | segment assets | at 2024-03-31 | ¥238m |
| Kirari Primereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥485m |
| Primary Care Homereportable segment | capex | 2023-04-01 → 2024-03-31 | ¥113m |
| Primary Care Homereportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥50m |
| Primary Care Homereportable segment | employees | at 2024-03-31 | 138 pure |
| Primary Care Homereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥883m |
| Primary Care Homereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥883m |
| Primary Care Homereportable segment | segment assets | at 2024-03-31 | ¥3.2bn |
| Primary Care Homereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥8m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥546m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥160m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥8.3bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥8.3bn |
| —segment total | segment assets | at 2024-03-31 | ¥5.4bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥552m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥166m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥8.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥8.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 18 pure |
| Home Visit Pharmacist Servicereportable segment | employees | at 2024-03-31 | 323 pure |
| Kirari Primereportable segment | employees | at 2024-03-31 | 27 pure |
| Primary Care Homereportable segment | employees | at 2024-03-31 | 138 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,145
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人トーマツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)宮本 芳樹 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)下平 雅和 | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)在宅訪問薬局事業の店舗固定資産の減損における将来キャッシュ・フローの見積り | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)【注記事項】（重要な会計上の見積り）固定資産の減損 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人トーマツ | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)宮本 芳樹 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)下平 雅和 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)在宅訪問薬局事業の店舗固定資産の減損における将来キャッシュ・フローの見積り | |
| Same as kam for consolidated fskam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior4YearDuration | － | JPY |
| Net sales (5-year summary) | Prior3YearDuration | － | JPY |
| Net sales (5-year summary) | Prior2YearDuration | － | JPY |
| Net sales (5-year summary) | Prior1YearDuration | － | JPY |
| Net sales (5-year summary) | CurrentYearDuration | 8285853000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration | － | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration | － | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration | － | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | － | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration | 716880000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior4YearDuration | － | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior3YearDuration | － | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior2YearDuration | － | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | － | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYearDuration | 441027000 | JPY |
| Comprehensive income (5-year summary) | Prior4YearDuration | － | JPY |
| Comprehensive income (5-year summary) | Prior3YearDuration | － | JPY |
| Comprehensive income (5-year summary) | Prior2YearDuration | － | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | － | JPY |
| Comprehensive income (5-year summary) | CurrentYearDuration | 441027000 | JPY |
| Net assets (5-year summary) | Prior4YearInstant | － | JPY |
| Net assets (5-year summary) | Prior3YearInstant | － | JPY |
| Net assets (5-year summary) | Prior2YearInstant | － | JPY |
| Net assets (5-year summary) | Prior1YearInstant | － | JPY |
| Net assets (5-year summary) | CurrentYearInstant | 1643125000 | JPY |
| Total assets (5-year summary) | Prior4YearInstant | － | JPY |
| Total assets (5-year summary) | Prior3YearInstant | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 17 of 17 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |